Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ZB001

Other · developed by Zenas BioPharma, LLC

Phase 1 Most advanced trial (none active)
ZBIO Developer
1 Registered trials

What is ZB001?

ZB001 is an investigational agent given as intravenous injections at 3 mg/kg and 10 mg/kg dose cohorts. It is studied in thyroid eye disease, also known as Graves ophthalmopathy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Ophthalmology
Developer
Zenas BioPharma, LLC (ZBIO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05776121 Phase 1 Thyroid Eye Disease Completed ZBIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Thyroid Eye Disease

More from Zenas BioPharma, LLC

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the ZBIO page.

Follow ZBIO, the company behind ZB001

See ZBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZBIO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.